Medtronic and NVIDIA Collaborate to Build AI Platform for Medical Devices
21 Marzo 2023 - 4:22PM
GTC—NVIDIA today announced that it is
collaborating with Medtronic, the world’s largest healthcare
technology provider, to accelerate the development of AI in the
healthcare system and bring new AI-based solutions into patient
care.
The companies will integrate NVIDIA healthcare and edge AI
technologies into Medtronic’s GI Genius™ intelligent endoscopy
module, developed and manufactured by Cosmo Pharmaceuticals. GI
Genius is the first FDA-cleared, AI-assisted colonoscopy tool to
help physicians detect polyps that can lead to colorectal
cancer.
GI Genius has been designed to host a suite of AI algorithms and
integrating the NVIDIA Clara™ healthcare platform could allow
Medtronic to scale development of algorithms for real-time
procedures, potentially accelerating AI innovation for better
patient care.
“Artificial intelligence is a powerful tool that can increase
the speed, efficiency and effectiveness of global health systems,”
said Kimberly Powell, vice president of healthcare at NVIDIA.
“We’re collaborating with Medtronic to accelerate AI innovation by
enabling a software-defined business model, with the goal of
improving clinical decision making, reducing medical variability
and driving better patient outcomes.”
“We believe that collaborating with AI companies and developers
like NVIDIA and Cosmo is essential to driving innovation within the
medical device industry,” said Giovanni Di Napoli, president of
Gastrointestinal Business at Medtronic. “We are committed to
working with the best and brightest minds in the field of AI to
develop new technologies that can improve patient outcomes and
transform the way we approach healthcare.”
Medtronic intends to integrate NVIDIA Holoscan — a real-time AI
computing software platform for building medical devices — and
NVIDIA IGX, an industrial-grade edge AI hardware platform, to run
with its GI Genius AI-assisted colonoscopy system to support
physicians with AI-enhanced diagnostic images. Holoscan helps bring
the latest AI applications into clinical settings by providing the
full-stack infrastructure needed for scalable, software-defined
processing of streaming data at the edge.
The NVIDIA Holoscan and IGX platform makes software-defined
medical devices possible by enabling developers to efficiently
train and validate AI models within the Cosmo Innovation Center,
and then host the AI-powered applications on Medtronic’s GI Genius
AI Access™ Platform, a marketplace for software-as-a-medical-device
(SaMD) applications.
The first GI Genius systems built with the NVIDIA technology
will be available later this year.
Watch NVIDIA founder and CEO Jensen Huang discuss the Medtronic
collaboration in his GTC keynote.
About NVIDIASince its founding in
1993, NVIDIA (NASDAQ: NVDA) has been a pioneer in accelerated
computing. The company’s invention of the GPU in 1999 sparked the
growth of the PC gaming market, redefined computer graphics,
ignited the era of modern AI and is fueling the creation of the
metaverse. NVIDIA is now a full-stack computing company with
data-center-scale offerings that are reshaping industry. More
information at https://nvidianews.nvidia.com/.
For further information, contact:Janette
CiborowskiNVIDIA
Corporation+1-734-330-8817jciborowski@nvidia.com
Certain statements in this press release including, but not
limited to, statements as to: the benefits, impact, and
availability of our products and technologies, including NVIDIA
Clara; NVIDIA Holoscan, and NVIDIA IGX; our collaboration with
Medtronic and the benefits and impact thereof; and the potential of
artificial intelligence to increase the speed, efficiency and
effectiveness of global health system are forward-looking
statements that are subject to risks and uncertainties that could
cause results to be materially different than expectations.
Important factors that could cause actual results to differ
materially include: global economic conditions; our reliance on
third parties to manufacture, assemble, package and test our
products; the impact of technological development and competition;
development of new products and technologies or enhancements to our
existing product and technologies; market acceptance of our
products or our partners' products; design, manufacturing or
software defects; changes in consumer preferences or demands;
changes in industry standards and interfaces; unexpected loss of
performance of our products or technologies when integrated into
systems; as well as other factors detailed from time to time in the
most recent reports NVIDIA files with the Securities and Exchange
Commission, or SEC, including, but not limited to, its annual
report on Form 10-K and quarterly reports on Form 10-Q. Copies of
reports filed with the SEC are posted on the company's website and
are available from NVIDIA without charge. These forward-looking
statements are not guarantees of future performance and speak only
as of the date hereof, and, except as required by law, NVIDIA
disclaims any obligation to update these forward-looking statements
to reflect future events or circumstances.
© 2023 NVIDIA Corporation. All rights reserved. NVIDIA, the
NVIDIA logo and NVIDIA Clara are trademarks and/or registered
trademarks of NVIDIA Corporation in the U.S. and other countries.
Other company and product names may be trademarks of the respective
companies with which they are associated. Features, pricing,
availability, and specifications are subject to change without
notice.
A photo accompanying this announcement is available at
https://www.globenewswire.com/NewsRoom/AttachmentNg/e044e56b-1849-4fbd-96d4-22bb445dc854
Grafico Azioni NVIDIA (NASDAQ:NVDA)
Storico
Da Mar 2024 a Apr 2024
Grafico Azioni NVIDIA (NASDAQ:NVDA)
Storico
Da Apr 2023 a Apr 2024